SNGX Soligenix Inc.

2.39
+0.3  (+14%)
Previous Close 2.09
Open 2.14
Price To Book 18.39
Market Cap 49,360,680
Shares 20,653,004
Volume 865,966
Short Ratio
Av. Daily Volume 207,467
Stock charts supplied by TradingView

NewsSee all news

  1. Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., Jan. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  2. Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    PRINCETON, N.J., Dec. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  3. CORRECTION FROM SOURCE: Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 13, 2019) - This news release has been corrected to add legal disclaimers. As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how

  4. Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 11, 2019) - As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ:SNGX) has achieved multiple milestones across the

  5. Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

    PRINCETON, N.J., Dec. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial complete.
SGX201
Radiation Enteritis
Phase 3 top-line data due 1Q 2020.
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3 top-line data due 2Q 2020.
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer
Phase 3 dependent on funding.
SGX203
Pediatric Crohn’s Disease
Phase 1c trial initiation announced December 12, 2019 with initial safety data due 2Q 2020 and longer-term safety and immunogenicity data due 4Q 2020.
RiVax
Ricin toxin vaccine

Latest News

  1. Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., Jan. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  2. Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    PRINCETON, N.J., Dec. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  3. CORRECTION FROM SOURCE: Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 13, 2019) - This news release has been corrected to add legal disclaimers. As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how

  4. Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 11, 2019) - As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ:SNGX) has achieved multiple milestones across the

  5. Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

    PRINCETON, N.J., Dec. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  6. Soligenix to Present at the PCG Spotlight Series Conference

    PRINCETON, N.J., Nov. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  7. Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results

    PRINCETON, N.J., Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  8. Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference

    PRINCETON, N.J., Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  9. Here's Why Soligenix Inc.'s SGX301 and SGX942 Can Change the CTCL and Oral Mucositis Treatment Landscape In A Matter of Months (NASDAQ: SNGX)

    Soligenix stock turns green ahead of two potential near-term catalysts. SGX301 and SGX942 late-stage data sets up company for strong 2020. Soligenix Inc. (NASDAQ:SNGX) stock has been enjoying upward momentum as data

  10. Video Report: Soligenix Inc. Bringing Two Catalysts Into View; SGX301 and SGX942 Can Change The CTCL and Oral Mucositis Treatment Landscape (NASDAQ: SNGX)

    Soligenix Inc. is in an enviable position of being the beneficiary of positive interim data from its two late-stage trials. And, if the topline data expected in the next 6-9 months can confirm interim analyses,

  11. Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer

    Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ:SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head

  12. Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada

    PRINCETON, N.J., Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  13. Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning

    PRINCETON, N.J., Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  14. Soligenix Appoints Jonathan Guarino as Chief Financial Officer

    PRINCETON, N.J., Sept. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  15. Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference

    PRINCETON, N.J., Aug. 29, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  16. Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

    PRINCETON, N.J., Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases